How did BioLineRx's revenue and expenses trend in Q4 2024?

BioLineRx's revenue and expenses in Q4 2024 showed a decrease in advertising and marketing expenses by 3.66%, with the last price being $3.16. However, R&D expenses remained at $1.87 million. The revenue by segment indicated a total of $22.92 million, with $12.7 million from license sales, $6.02 million from product sales, and $4.49 million from other business activities.

|code|Ticker|Name|Date|Business Composition|Revenue By Business|market_code|
|---|---|---|---|---|---|---|
|BLRX|BLRX.O|BioLineRx|20240101-2024|Product Sales, Net|6023000|186|
|BLRX|BLRX.O|BioLineRx|20240101-2024|Product Sales, Net|4489000|186|
|BLRX|BLRX.O|BioLineRx|20240101-2024|Product Sales, Net|2767000|186|

|code|Ticker|Name|Date|R&D Expenses|market_code|
|---|---|---|---|---|---|
|BLRX|BLRX.O|BioLineRx|2024 Q1|2494000|186|
|BLRX|BLRX.O|BioLineRx|2024 Q2|2225000|186|
|BLRX|BLRX.O|BioLineRx|2024 Q3|2565000|186|
|BLRX|BLRX.O|BioLineRx|2024 Q4|1865000|186|